RXO, Inc. filings document the formal disclosures of an NYSE-listed asset-light transportation company with common stock traded under RXO. Recent Form 8-K reports furnish quarterly operating results, related investor presentations, Regulation FD materials, senior unsecured notes disclosures, and asset-based revolving credit facility agreements tied to the company's transportation brokerage and logistics operations.
Proxy materials disclose board elections, auditor ratification, executive compensation votes and amendments to the RXO, Inc. 2022 Omnibus Incentive Compensation Plan. Other material-event filings cover officer appointments, subsidiary guarantees, debt redemption terms, collateral and borrowing-base mechanics, and capital-structure disclosures involving senior notes and revolving credit arrangements.
RXO, Inc. reported an insider equity award for one of its directors. On January 2, 2026, the director received 14,517 restricted stock units (RSUs), each representing the right to receive either one share of common stock or a cash payment equal to its fair market value upon settlement.
The RSUs vest in full on January 2, 2027, as long as the director continues serving on the board, and the award is subject to a deferral election that can delay share delivery. After this grant, the director beneficially owns 41,844 RSUs tied to common stock, including 7,745 RSUs that vested on January 2, 2026 but are deferred under a similar election.
RXO, Inc. director equity activity: A board member reported changes in ownership of RXO common stock tied to restricted stock units (RSUs). On January 2, 2026, 7,745 RSUs vested in full and were settled into 7,745 shares of common stock at a stated price of $0 per share, increasing directly held common shares to 30,875.
The filing also shows a new grant of 14,517 RSUs on January 2, 2026. These RSUs are scheduled to vest in full on January 2, 2027, subject to the director’s continued service on the board and a deferral election. Upon settlement, each RSU will deliver either one share of RXO common stock or a cash amount equal to the fair market value of one share, as provided in the award terms.
RXO, Inc. director received a new equity award in the form of restricted stock units. On January 2, 2026, the reporting person was granted 14,517 restricted stock units (RSUs), each representing the right to receive either one share of RXO common stock or a cash amount equal to the share’s fair market value upon settlement. The RSUs were granted at a price of $0, reflecting that this is a compensation award rather than a market purchase.
The RSUs will vest in full on January 2, 2027, provided the individual continues to serve as a director. Delivery of the underlying common shares is subject to a deferral election, meaning the director chose to receive the shares or cash at a later date under the plan’s terms. After this award, the director beneficially holds 22,262 derivative securities, which include RSUs tied to 7,745 shares that vested on January 2, 2026 and are also subject to a deferral election.
RXO, Inc. director reported equity compensation activity involving company stock. On 01/02/2026, the director acquired 7,745 shares of Common Stock at an exercise price of $0, leaving a total of 35,137 shares of Common Stock beneficially owned directly after the transaction.
The filing also shows derivative awards in the form of restricted stock units (RSUs). On the same date, the director received 14,517 RSUs, each representing a right to one share of Common Stock or its cash value, which are scheduled to vest in full on January 2, 2027, subject to continued board service. An existing RSU award of 7,745 units vested on January 2, 2026, resulting in the corresponding share acquisition.
RXO, Inc. reported that one of its directors received a grant of restricted stock units on January 2, 2026. The grant covers 14,517 restricted stock units (RSUs), each representing a contingent right to receive either one share of RXO common stock or a cash payment equal to the fair market value of one share upon settlement.
The RSUs are scheduled to vest in full on January 2, 2027, subject to the director’s continued service on the board and a deferral election. Following this transaction, the director beneficially owns 148,522 derivative securities, including RSUs tied to 7,745 shares of common stock that vested on January 2, 2026 but are subject to a deferral election, with delivery of shares to follow the applicable deferral terms.
RXO, Inc. reported that one of its directors completed several equity transactions on January 2, 2026. The director acquired 7,745 shares of common stock at a stated price of $0 through the exercise of derivative awards and, after this transaction, directly held 283,161 common shares.
On the same date, the director was granted 14,517 restricted stock units (RSUs), each representing a right to receive either one share of common stock or a cash amount equal to its fair market value. These RSUs are scheduled to vest in full on January 2, 2027, subject to continued service as a director. A prior RSU award covering 7,745 units vested on January 2, 2026, resulting in the corresponding common shares being issued.
RXO, Inc. reported an insider equity transaction by one of its directors on 01/02/2026. The director acquired 7,745 shares of common stock at a price of $0 through the conversion of previously granted restricted stock units (transaction code M), bringing direct ownership to 34,275 common shares.
On the same date, the director received a new award of 14,517 restricted stock units (RSUs), each representing the right to receive either one share of common stock or a cash payment equal to its fair market value upon settlement. These RSUs are scheduled to vest in full on January 2, 2027, provided the director continues to serve on the board. Previously granted RSUs vested on January 2, 2026, triggering the share acquisition.
RXO, Inc. (RXO) director reported an open-market purchase of company stock. On 11/20/2025, the reporting person bought 8,317 shares of RXO common stock in a transaction coded "P" (purchase), at a weighted average price of $10.61 per share, within a price range of $10.45 to $10.75.
Following this transaction, the director beneficially owns 275,416 shares of RXO common stock directly. The filing notes that detailed trade data by price level is available upon request.
RXO, Inc. director reported an open-market purchase of 9,350 shares of common stock on 11/17/2025 at a weighted average price of $10.75, bringing direct ownership to 91,137 shares.
The filing also shows beneficial ownership of restricted stock units (RSUs), including 7,745 RSUs that vest in full on January 2, 2026, and 126,260 RSUs that have vested and are subject to a deferral election. Each RSU represents the right to receive either one share of RXO common stock or a cash amount equal to its fair market value upon settlement.
The amendment was made solely to voluntarily include the director’s beneficial ownership of RSUs reported in Table II.
RXO, Inc. reported an insider share purchase by a company director. On 11/17/2025, the reporting person bought 9,350 shares of RXO common stock in the open market, coded as a purchase transaction.
The weighted average purchase price was $10.75 per share, with individual trades ranging from $10.74 to $10.76. Following this transaction, the director directly beneficially owns 91,137 shares of RXO common stock.